Rosetta Capital IV

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, founded in 2011. The company focuses on developing pharmaceutical therapies, particularly sevuparin, a novel treatment for sickle cell disease, a painful inherited blood disorder affecting millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is exploring the potential of sevuparin to address other conditions characterized by severe systemic inflammation, including sepsis, endotoxemia, severe malaria, and anemia related to chronic inflammation. The company's innovative approach aims not only to improve patient outcomes but also to reduce healthcare costs associated with these serious medical conditions. Modus Therapeutics operates as a subsidiary of Dilafor AB.

Dilafor AB is a Swedish drug development company based in Solna, founded in 2003. The company specializes in creating pharmaceutical products for obstetric indications, with a primary focus on tafoxiparin. This product is designed as an adjuvant therapy to promote cervical ripening and myometrial contractility, aiming to decrease the incidence of slow progress of labor both after induction and spontaneous onset. Dilafor investigates and exploits the pharmacological properties of low anticoagulant heparin derivatives in obstetrics, contributing to healthier outcomes for mothers, children, and families by reducing risks associated with protracted labor.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative treatments for premenstrual dysphoric disorder (PMDD) and other conditions related to hormonal fluctuations. The company's primary focus is on Sepranolone, a therapeutic agent designed to address the challenges associated with PMDD. In addition to Sepranolone, Asarina is advancing a second-generation oral compound in preclinical development aimed at PMDD. The company's research is rooted in over 40 years of studies on Allopregnanolone-related neurological disorders, and it is also working on a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These efforts aim to create effective and safe treatments for various neuroendocrinological conditions that remain inadequately addressed in the current medical landscape.

Biosergen AS is a biotechnology company focused on the development of innovative antifungal drugs, leveraging advanced biopharmaceutical research and development. Based in Trondheim, Norway, with additional facilities worldwide, Biosergen is working on a range of products, including S44HP, an antibiotic that exhibits enhanced potency against various fungal pathogens compared to traditional nystatin. The company is also developing BSG005, a potentially disruptive antifungal drug that has shown significant safety and efficacy benefits over existing treatments. Additionally, Biosergen explores nystatin analogues through genetic manipulation of nystatin biosynthetic genes, aiming to improve therapeutic options in the antifungal market.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

EyeSense AG specializes in the development of ophthalmic diagnostic systems aimed at improving glucose testing for diabetic patients. The company focuses on creating innovative, pain-free blood glucose monitoring devices that facilitate better diabetes management. By utilizing advanced fiber optic sensors, EyeSense AG's technology enables continuous blood sugar measurement, thereby enhancing the therapy and care available to individuals with diabetes.